Evaluation of long-acting somatostatin analog injection devices by nurses: A quantitative study

Medical Devices: Evidence and Research

Volumn 5, Issue 1, 2012, Pages 103-109

  Adelman, Daphne T ^a   Burgess, Andrea ^b   Davies, Philippa R ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Device; Lanreotide; Nurse; Octreotide; Somatostatin analog

Indexed keywords

DEVICE; LANREOTIDE; NURSE; OCTREOTIDE; SOMATOSTATIN ANALOG;

NURSING;

ANGIOPEPTIN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ARTICLE; CARCINOID SYNDROME; CHRONIC PANCREATITIS; CONTROLLED STUDY; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SCREENING; DRUG SYNTHESIS; EUROPE; HUMAN; HYPOPHYSIS TUMOR; INTERVIEW; MAJOR CLINICAL STUDY; NEUROENDOCRINE TUMOR; NURSE; PANCREAS DISEASE; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; UNITED STATES;

EID: 84871494650     PISSN: None     EISSN: 11791470     Source Type: Journal    
DOI: 10.2147/MDER.S37831     Document Type: Article

References (13)

1. Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355(24): 2558-2573.
2. Grozinsky-Glasberg S, Grossman AB, Korbonits M. The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol. 2008;286(1-2):238-250.
3. Somatuline® Depot (lanreotide) injection [prescribing information]. Paris: Ipsen Pharma; 2011.
4. Biermasz NR, van den Oever NC, Frolich M, et al. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin Endocrinol (Oxf). 2003;58(3): 228-295.
5. Turner HE, Thornton-Jones VA, Wass JA. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol (Oxf). 2004;61(2): 224-231.
6. Morgan G, Cooley C. Injection systems for two luteinising hormone-releasing hormone agonists: a comparative assessment of administration times and nurses' perceptions. Eur J Oncol Nurs. 2005;9(4): 334-340.
7. Dumas H, Panayiotopoulos P, Parker D, Pongpairochana V. Understanding and meeting the needs of those using growth hormone injection devices. BMC Endocr Disord. 2006;6:5.
8. Novartis AG. Sandostatin® LAR®: mixing. 2012. Available from: http://www.sandostatin.com/about-sandostatin-lar/sandostatin-lar-mixing.jsp?lightbox=global-hcp. Accessed September 4, 2012.
9. Bevan JS, Newell-Price J, Wass JA, et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf). 2008;68(3):343-349.
10. Salvatori R, Nachtigall LB, Cook DM, et al. Effectiveness of self-or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary. 2010;13(2):115-122.
11. Tuvia S, Atsmon J, Teichman SL, et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab. 2012;97(7):2362-2369.
12. Schweinsberg K, Smith S, Kirshner LS. Ease of administration of somatostatin analogs, octreotide LAR versus lanreotide [abstract]. Endocr Rev. 2011;32(03_Meeting Abstracts):P1-P451.
13. Marty R, Roze S, Kurth H. Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK. Medical Devices (Auckl). 2012;5: 39-44.